Highlights

Mid-term review sets future direction

Mid-term review sets future direction

A comprehensive independent assessment found the Centre to be performing at a high level, producing distinct and positive ben...

read the full story

Smarter drug design

Smarter drug design

An advanced experimental technique linked to high powered computation is becoming an increasingly important tool for MWC rese...

read the full story

High-impact publications highlight TB research

High-impact publications highlight TB research

Researchers in the MWC’s Tuberculosis Flagship Research Programme have had their long hours in the lab recognised through pub...

read the full story

Investigating a bacterial 'master' of disguise

Investigating a bacterial 'master' of disguise

MWC researchers have revealed a unique protein in a common bacterium that helps it disguise itself from immune attack. This d...

read the full story

Re-thinking the causes of rheumatic fever

Re-thinking the causes of rheumatic fever

Researchers and health professionals are re-thinking the causes of rheumatic fever after studies by Maurice Wilkins Centre in...

read the full story

Advancing a vaccine for rheumatic fever (2013)

Advancing a vaccine for rheumatic fever (2013)

In 2013 the Maurice Wilkins Centre hosted a symposium attended by world experts in rheumatic fever. It marked the start of a ...

read the full story

Stepping up the fight: The Tuberculosis Flagship (2013)

Stepping up the fight: The Tuberculosis Flagship (2013)

The Maurice Wilkins Centre is behind the launch of a national research network of ‘serious intellectual muscle’ that aims to ...

read the full story

PhD student part of international drug development programme (2012)

PhD student part of international drug development programme (2012)

Maurice Wilkins Centre-funded PhD student Matthew Bull is part of international research on a new class of immunosuppressants...

read the full story

New Zealand TB drug candidate selected (2012)

New Zealand TB drug candidate selected (2012)

In late 2012 a promising New Zealand compound targeting treatment-resistant tuberculosis (TB) was selected as a drug candidat...

read the full story